Trial Profile
A Study Comparing Clinical Outcomes of Erlotinib Versus Gefitinib in Epidermal Growth Factor Receptor-Mutant Non-Small Cell Lung Cancer Patients with Brain Metastasis
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 13 Jul 2017
Price :
$35
*
At a glance
- Drugs Erlotinib (Primary) ; Gefitinib (Primary)
- Indications Brain metastases; Non-small cell lung cancer
- Focus Adverse reactions; Therapeutic Use
- 13 Jul 2017 New trial record
- 24 May 2017 Results presented at the 113th International Conference of the American Thoracic Society.